<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="320958">
  <stage>Registered</stage>
  <submitdate>17/03/2010</submitdate>
  <approvaldate>19/03/2010</approvaldate>
  <actrnumber>ACTRN12610000234011</actrnumber>
  <trial_identification>
    <studytitle>The Australian Ultraviolet Radiation and Immunity Study</studytitle>
    <scientifictitle>Assessing in healthy young Australian adults whether exposure to solar ultraviolet radiation (UVR) at levels relevant to normal daily activities affects immune response to primary vaccination.</scientifictitle>
    <utrn>U1111-1114-4701</utrn>
    <trialacronym>AusUVI</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Impact of solar ultraviolet radiation on human primary immune response to immunisation with a T-cell dependent antigen (Keyhole Limpet Hemocyanin or KLH)</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Normal development and function of the immune system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Participants will wear a ultraviolet radiation (UVR) absorbant wrist band which will measure UVR personal exposure for 5 days.  Subsequently all participants will be vaccinated subcutaneously with 125mcg keyhole limpet hemocyanin (KLH) administered to a sun exposed part of the forearm.  Participants will be recruited over a 52 week period.</interventions>
    <comparator>We are correlating UVR exposure against immune response to vaccination. There is not control group.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Humoral response to primary subcutaneous vaccination with Keyhole Limpet Hemocyanin (KLH). KLH-specific immunoglobulins (Ig) (Ig types M, E, G and subsets) will be quantified via enzyme linked immunoassay techniques.</outcome>
      <timepoint>KLH specific antibody titres taken at baseline (immediately prior to vaccination which follows the 5 days of UVR exposure measurement); 1 week and 3 weeks post vaccination</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Delayed-type hypersensitivity (DTH) response to intra-dermal KLH will be measured in millimetres of skin reaction</outcome>
      <timepoint>Intradermal KLH given at day 21 post vaccination. DTH response read at 48 hours post intradermal KLH.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>KLH specific T-cell response will be measured via lymphocyte proliferation assays and cytokine production.</outcome>
      <timepoint>Measured at baseline (immediately prior to vaccination) and day 21.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>* Age 18 - 40 years
* Healthy 
* Willing and able to sign informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>40</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>* Allergy to shellfish 
* Pregnancy or breastfeeding 
* Previous KLH vaccination 
* Immunosuppressive medications 
* Immunosuppressive medical condition 
* Recent infection (within 2 weeks of vaccination) 
* Recent immunisation with any other vaccine in past 4 weeks 
* Photosensitive skin or taking photosensitsing medication</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>15/06/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>210</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>0200</postcode>
    <postcode>2605</postcode>
    <postcode>4814</postcode>
    <postcode>4811</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Robyn Lucas</primarysponsorname>
    <primarysponsoraddress>National Centre for Epidemiology and Population Health
Building 62
Australian National University
Canberra
Australian Capital Territory 0200</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Research and Medical Research Council</fundingname>
      <fundingaddress>National Health and Medical Research Council
GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr Ashwin Swaminathan</sponsorname>
      <sponsoraddress>National Centre for Epidemiology and Population Health
Building 62
Australian National University
Canberra
Australian Capital Territory 0200</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study assesses whether exposure to solar ultraviolet radiation at levels relevant to normal daily activities can suppress the immune response to vaccination in young, healthy adults.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Australian National University Human Research Ethics Committee</ethicname>
      <ethicaddress>Research Office
Level 3
Innovations Building (124)
Corner Eggleston and Garran Roads
Australian National University
Acton Australian capital Territory
0200</ethicaddress>
      <ethicapprovaldate>4/02/2010</ethicapprovaldate>
      <hrec>2009/628</hrec>
      <ethicsubmitdate>13/01/2010</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ashwin Swaminathan</name>
      <address>National Centre for Epidemiology and Population Health
Building 62
Australian National University
Canberra 
Australian Capital Territory
0200</address>
      <phone>+61 2 6125 2378</phone>
      <fax>+61 2 6125 0740</fax>
      <email>ashwin.swaminathan@anu.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Ashwin Swaminathan</name>
      <address>National Centre for Epidemiology and Population Health
Building 62
Australian National University
Canberra 
Australian Capital Territory
0200</address>
      <phone>+61 2 61252378</phone>
      <fax>+61 2 6125 0740</fax>
      <email>ashwin.swaminathan@anu.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ashwin Swaminathan</name>
      <address>National Centre for Epidemiology and Population Health
Building 62
Australian National University
Canberra 
Australian Capital Territory
0200</address>
      <phone>+61 2 61252378</phone>
      <fax>+61 2 61250740</fax>
      <email>ashwin.swaminathan@anu.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>